Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Unusual Ovarian Cancer Relapse Managed by Nivolumab in a Long-term Surviving Patient with PD-L1 Mutation.

Chinese medical journal - 5 May 2017

Yang Jie, Yang Jun-Jun, Zhao Jun, Ren Tong, Feng Feng-Zhi, Wan Xi-Run, Xiang Yang

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antibodies, Monoclonal
Share to B7-H1 Antigen
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Recurrence, Local

Share to Nivolumab

Share to Ovarian Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 28469110
DOI: 10.4103/0366-6999.204922
PMCID: PMC5421185

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Unusual Ovarian Cancer Relapse Managed by Nivolumab in a Long-term Surviving Patient with PD-L1 Mutation.PMID 28469110Read ↗

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review.Semantic proximity Read ↗

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinomaSemantic proximity Read ↗

Checkpoint-inhibition in ovarian cancer: rising star or just a dream?Semantic proximity Read ↗

Ovarian Mesonephric-Like Adenocarcinoma: Its Prevalence and a Literature Review on Therapeutic TargetsSemantic proximity Read ↗

Malignant ovarian and testicular germ cell tumors: Common characteristics but different prognosesSemantic proximity Read ↗

Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives.Semantic proximity Read ↗

Actualities in Ovarian Cancer in the Perspective of 2015 (ASCO and ECCO).Semantic proximity Read ↗

[Gynecologic malignancies].Semantic proximity Read ↗

Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement.Semantic proximity Read ↗

Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers: The Early Experience of Two Academic CenterSemantic proximity Read ↗

A NOTCH1 Mutation Found in a Newly Established Ovarian Cancer Cell Line (FDOVL) Promotes Lymph Node Metastasis in Ovarian Cancer.Semantic proximity Read ↗

Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 2018.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.